People with migraine often speak not only of the pain and physical burden of migraine, but also the emotional toll it exerts on their lives. Migraine robs people of time away from work, school and, most importantly, lost time with their family and friends. What’s more, migraine is a disease that is often misunderstood, creating an unfair and false stigma that compounds the patient burden.

As the first and only CGRP receptor antagonist in a fast-acting orally disintegrating tablet (ODT) for the acute and preventive treatment of migraine, Nurtec® ODT (rimegepant) combined its unique chemical molecule with innovation in drug design to deliver:

1) an easy-to-use oral medication that doesn’t need to be swallowed (especially important in people with migraine who experience nausea and/or vomiting);

2) rapid onset of action with return to normal by 60 minutes for many patients due to the ODT quick absorption; and

3) sustained efficacy lasting 48 hours after a single dose for many patients.

Patient-focused drug design

Nurtec ODT is a differentiated therapy born from the innovative culture and patient-first mission that is Biohaven’s hallmark. In developing Nurtec ODT, the company spent significant time understanding the patient journey in migraine. This informed Biohaven’s blueprint for Nurtec ODT and provided the impetus for the ODT formulation strategy that makes it stand apart in the CGRP antagonist class.

Meeting patient needs

Nurtec ODT is distinguished by its proprietary ODT formulation and its ability to provide the rapid onset and duration effect that people with migraine had long sought. Delivered as a fast-dissolving tablet, Nurtec ODT can be taken – without water – wherever and whenever a migraine attack starts, and works fast.

Nurtec ODT is contraindicated in patients with a history of hypersensitivity to rimegepant, Nurtec ODT, or to any of its components. Nurtec ODT may cause serious side effects including allergic reactions, including trouble breathing and rash. This can happen days after you take Nurtec ODT. Call your HCP or get emergency help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing. This occurred in less than 1% of patients treated with Nurtec ODT.

Treating the full spectrum of migraine disease

In 2021, Biohaven reached a significant milestone in its rimegepant program, receiving FDA approval for Nurtec ODT for the preventive treatment of episodic migraine in adults. This approval makes Nurtec ODT the first oral CGRP antagonist approved for the preventive treatment of migraine, and the only migraine medication approved as a dual therapy for both acute and preventive treatment. Since approximately 95 percent of all US migraine patients experience less than 15 headache days per month, the dual indication significantly expands the market potential of Nurtec ODT and provides a more complete, flexible treatment plan for the vast majority of people with migraine, giving them increased control of their disease.

Nurtec® ODT 75 mg orally disintegrating tablets is a prescription medicine that is used to treat migraine in adults. It is for the acute treatment of migraine attacks and the preventive treatment of episodic migraine. Do not take if you are allergic to Nurtec ODT or any of its ingredients. The most common side effects were nausea (2.7%) and stomach pain/indigestion (2.4%). For more information, please see Prescribing Information.

© 2022 Biohaven Pharmaceuticals, Inc. All rights reserved. NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC. Biohaven is a trademark of Biohaven Pharmaceutical Holding Company Ltd. US-RIMODT-2200001 01/06/2022